GOG-0260

Terminated

Return to Protocol Table

A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Principal Investigator

Bradley J. Monk

Status

Terminated

Open to Accrual

June 17, 2013

Closed to Accrual

March 16, 2015

Closed to Accrual & Treatment

January 22, 2016

Complete

February 9, 2019

Terminated

November 14, 2019


Disease Site

Gynecologic [GY] Ovarian

Phase

II

Developmental Therapeutics

No

Primary Objective

To estimate the antitumor activity of elesclomol and paclitaxel in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer primarily through the frequency of objective tumor responses.

To determine the nature and degree of toxicity of elesclomol and paclitaxel in this cohort of patients.

Patient Population

Patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer primarily through the frequency of objective tumor responses.

Target Accrual

55

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.